The investment round was led by White Star Capital with participation from Novator, Vostok New Global, Anthemis Exponential, Colle Capital, and Hanwha Dream Fund.
"We started Numan three years ago to help men take better care of themselves. Since then we’ve had a positive impact on the lives of hundreds of thousands of men in the UK, and have been humbled and inspired by the response that the Numan offering has had. This funding is a significant milestone on our journey to help millions of men be healthier. White Star Capital is one of the best investors in our space, and I’m delighted to be working together along with a wider team of brilliant investors. We now have the team, product, technology, and investor base to accelerate Numan’s growth and fulfill the potential of our vision."
The oversubscribed financing round will support the commercialisation of proprietary breath biopsy tests.
"We are thrilled to have the support of such highly respected investors as we strive to have a major impact on patient outcomes and the efficient delivery of healthcare resources and are very pleased to now welcome the experience and insight of Horizons’ Patrick Zhang to our Board."
The extension round includes backing from Blume Equity and existing investors to support the brand's growth.
"Elvie is ready for the next phase of our growth. We have already revolutionized the categories we operate in, but we know that there is vast untapped potential to create better technology products and services for women in new areas."
The funding round was led by Faber with participation from Ganexa Capital and Innovate UK.
"As it stands, the management of long-term health conditions is an inefficient process for patients and their GP practice. It involves multiple appointments, duplication of tests, and tons of admin. It doesn’t deliver the best for patients and also wastes valuable NHS time and resources. Abtrace is working at the interface of AI and healthcare to transform this."
